Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EAN 2020

23–26 May 2020 | Virtual Meeting

EAN 2020

23–26 May 2020 | Virtual Meeting
Unmet needs in Parkinson’s disease 2:31
Unmet needs in Parkinson’s disease
K. Ray Chaudhuri • 29 May 2020
PROMISE-1: eptinezumab in episodic migraine 2:44
PROMISE-1: eptinezumab in episodic migraine
Messoud Ashina • 29 May 2020
Late-stage Parkinson’s disease: management strategies 2:03
Late-stage Parkinson’s disease: management strategies
Margherita Fabbri • 15 May 2020
Understanding migraines better with AI 0:58
Understanding migraines better with AI
Dagny Holle-Lee • 20 May 2020
Diagnosis of multiple sclerosis: McDonald criteria 4:01
Diagnosis of multiple sclerosis: McDonald criteria
Celia Oreja-Guevara • 24 May 2020
Sleep disorders: VDR gene FokI polymorphism 1:07
Sleep disorders: VDR gene FokI polymorphism
Bárbara Guerra Leal • 21 May 2020
Long-term effectiveness of levodopa-carbidopa intestinal gel in Parkinson’s disease 2:37
Long-term effectiveness of levodopa-carbidopa intestinal gel in Parkinson’s disease
Angelo Antonini • 20 May 2020
Impaired circadian heart rate variability in Parkinson’s Disease 2:27
Impaired circadian heart rate variability in Parkinson’s Disease
Valentina Arnao • 29 May 2020
Fremanezumab in patients with chronic or episodic migraine 2:52
Fremanezumab in patients with chronic or episodic migraine
Uwe Reuter • 22 May 2020
OPTIPARK trial: opicapone in clinical practice 3:59
OPTIPARK trial: opicapone in clinical practice
Georg Ebersbach • 27 May 2020
CONQUER: galcanezumab in treatment-resistant migraine 9:29
CONQUER: galcanezumab in treatment-resistant migraine
Stewart Tepper • 24 May 2020
Are patients with advanced Parkinson’s disease identified early enough? 2:18
Are patients with advanced Parkinson’s disease identified early enough?
Per Odin • 27 May 2020
Peripheral neuropathy and Parkinson’s: α-synuclein aggregation 1:06
Peripheral neuropathy and Parkinson’s: α-synuclein aggregation
Marta Francisca Corrà • 23 May 2020
ALS and FTD: current treatment landscape 1:40
ALS and FTD: current treatment landscape
Yuliya Shpilyukova • 17 May 2020
HER-MES study: erenumab versus topiramate in episodic migraine 2:30
HER-MES study: erenumab versus topiramate in episodic migraine
Uwe Reuter • 22 May 2020
Pediatric versus adult multiple sclerosis 1:24
Pediatric versus adult multiple sclerosis
Tanuja Chitnis • 24 May 2020
The content of VJNeurology is intended for healthcare professionals